BackRelmada Therapeutics Overview
Relmada Therapeutics Inc

Relmada Therapeutics Target Price

See Relmada Therapeutics's analyst price targets ($12) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$5.3

Average Target Price

$12.00126.4% upside

1 analysts in the last 4 months

High: $12 | Low: $12

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-18H.C. Wainwright$12126.4% upsideOpen
2026-03-13Mizuho SecuritiesUy Ear$1088.7% upsideOpen
2026-01-23Leerink Partners$850.9% upsideOpen
2025-12-22Jefferies$969.8% upsideOpen
2024-06-05Goldman SachsAndrea Tan$262.3% downsideOpen
2022-10-13JefferiesAndrew Tsai$850.9% upsideOpen
2022-10-13OppenheimerJay Olson$732.1% upsideOpen

Relmada Therapeutics (RLMD) FAQ

As of the most recent data, RLMD shows a target price of $12. Scroll down for historical charts and peer comparison views.

If Relmada Therapeutics moved to the average analyst target of $12, shares would be roughly 126.4% higher than $5.3. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Relmada Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Relmada Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $12) with ownership activity and broader fundamentals.

Relmada Therapeutics's target price is $12; compare it with other Consumer Discretionary names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.